Pirarubicin
|
|
|
- CAS-Nr.
- 72496-41-4
- Englisch Name:
- Pirarubicin
- Synonyma:
- Therarubicin;PIRARUBICIN HYDROCHLORIDE;(8S,10S)-10-[(2S,4S,5S,6S)-4-Amino-6-methyl-5-[(2S)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione;(8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;1609rb;CS-702;THP-ADM;Pirabucin;Pirarubcin;THEPRUBICIN
- CBNumber:
- CB7315796
- Summenformel:
- C32H37NO12
- Molgewicht:
- 627.64
- MOL-Datei:
- 72496-41-4.mol
|
Pirarubicin Eigenschaften
- Schmelzpunkt:
- 188-192°C (dec.)
- alpha
- D25 +175 ±25° (c = 0.2 in CHCl3)
- Siedepunkt:
- 834.7±65.0 °C(Predicted)
- Dichte
- 1.51±0.1 g/cm3(Predicted)
- storage temp.
- 2-8°C
- Löslichkeit
- ethanol: soluble25mg/mL
- Aggregatzustand
- powder
- pka
- 7.35±0.60(Predicted)
- Farbe
- Orange to Red
- Stabilität:
- Hygroscopic
Pirarubicin Chemische Eigenschaften,Einsatz,Produktion Methoden
R-Sätze Betriebsanweisung:
R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut.
S-Sätze Betriebsanweisung:
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S37/39:Bei der Arbeit geeignete Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
Beschreibung
Pirarubicin is a new anthracycline anticancer agent structurally related to doxorubicin. In
acute leukemia, non-Hodgkin’s lymphoma, breast and ovariail carcinoma, pirarubicin is
reportedly superior to doxorubicin and better tolerated. Its major side-effect appears to be
myelosuppression, mainly in the form of leucopenia, which is potentially dose-limiting.
Chemische Eigenschaften
Red Solid
Pirarubicin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Pirarubicin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 262)Lieferanten
72496-41-4()Verwandte Suche:
(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-tridesoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxynaphthacen-5,12-dionhydrochlorid
Doxorubicin
2-(Hydroxymethyl)anthrachinon
1,2,3,4-Tetrahydronaphthalin-1,5-diol
1,8-Dihydroxy-3-methylanthrachinon
1,4,5-Trihydroxy-2-methylanthrachinon
- THP-ADM
- THEPRUBICIN
- (8s-cis)-droxyacetyl)-1-methoxy
- Tepirubicin
- Therarubiein
- THP-adriamycin
- 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L- lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
- (8S)-10α-[[3-Amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8β-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
- (8S,10S)-10α-[[3-Amino-4-O-(tetrahydro-2H-pyran-2-yl)-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8β-hydroxyacetyl-1-methoxy-5,12-naphthacenedione
- Pirarubicin(THP-AdriaMycin)
- (7S,9S)-7-((2R,4S,5S,6S)-4-amino-6-methyl-5-((R)-tetrahydro-2H-pyran-2-yloxy)-tetrahydro-2H-pyran-2-yloxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
- PIRARUBICIN
- 1609rb
- 4’-o-tetrahydropyranyladriamycin
- 4’-o-tetrahydropyranyldoxorubicin
- 5,12-naphthacenedione,10-((3-amino-2,3,6-trideoxy-4-o-(tetrahydro-2h-pyran-2-y
- l)-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hy
- Pirarubicin(BICINS)
- (8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
- Pinorubicin
- Pirabucin
- 5,12-Naphthacenedione, 10-3-amino-2,3,6-trideoxy-4-O-(2R)-tetrahydro-2H-pyran-2-yl-.alpha.-L-lyxo-hexopyranosyloxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
- (8S)-10-[(2S,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione
- CS-702
- Pirarubcin
- 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
- Pirarubicin USP/EP/BP
- (8S,10S)-10-(((2R,4S,5S,6S)-4-Amino-6-methyl-5-(((R)-tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
- PIRARUBICIN HYDROCHLORIDE
- Therarubicin
- (8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
- (8S,10S)-10-[(2S,4S,5S,6S)-4-Amino-6-methyl-5-[(2S)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione
- Pirarubicin Topoisomerase II inhibitor ab142734
- Famoxadone Impurity 14
- THP-Doxorubicin
- 72496-41-4
- C32H37NO12
- Inhibitors
- API
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Chiral Reagents
